メニューにジャンプコンテンツにジャンプ

トップページ > 診療科・部門 > 診療科(内科系) > 放射線核医学科 > 研究業績 > 2016年 研究業績

2016年 研究業績

原著論文-英文

  1. Minamimoto R, Iagaru A, Jamali M, Holley D, Barkhodari A, Vasanawala S, Zaharchuk G.
    Conspicuity of Malignant Lesions on PET/CTand Simultaneous Time-of-flight PET/MRI.
    PLoS One. 2016, in press.
  2. Mansi R, Minamimoto R, Mäcke H, Iagaru AH.
    Bombesin-Targeted PET of Prostate Cancer.J
    Nucl Med. 2016 Oct;57(Suppl 3):67S-72S.
  3. Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K, Minamimoto R, Arakawa A, Tominaga M, Arai H.
    Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors.
    Ann Nucl Med. 2016 Nov;30(9):608-618 
  4. Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H.
    Update on advances in molecular PET in urological oncology.
    Jpn J Radiol. 2016 Jul;34(7):470-85.
  5. Minamimoto R, Barkhodari A, Harshman L, Srinivas S, Quon A.
    Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
    PLoS One. 2016 Apr 28;11(4):e0153321.
  6. Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Kubota Y, Inoue T, Yao M.
    FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma.
    BMC Cancer. 2016 Feb 8;16:67.
  7. Ito K, Kubota K.
    18F-FDG PET/CT Findings in 2 Cases With Myelodysplastic Syndrome Accompanied by Behçet's Disease.
    Clin Nucl Med. Feb 24, 2016.
  8. Minamimoto R, Levin C, Jamali M, Holley D, Barkhodari A, Zaharchuk G, Iagaru A.
    Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI.
    Mol Imaging Biol. 2016.
  9. Minamimoto R, Mitsumoto T, Miyata Y, Sunaoka F, Morooka M, Okasaki M, Iagaru A, Kubota K.
    Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image.
    Nucl Med Commun. 37(2) :162-170, 2016.
  10. Minamimoto R, Nakaigawa N, Nagashima Y, Toyohara J, Ueno D, Namura K, Nakajima K, Yao M, Kubota K.
    Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: Preliminary study.
    Abdominal Radiology. 41(3):521-30, Mar, 2016.
  11. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, Hankins J, Mottaghy F, Juweid M, Quon A.
    Prospective multicenter comparison of early interim 18F-FLT PET/CT versus 18F-FDG PET/CT using IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring of diffuse large B-cell lymphoma.
    Radiology. 2016 Jul;280(1):220-9.
  12. Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, Iagaru A.
    Pilot Prospective Evaluation of 18F FPPRGD2 PET/CT in Patients with Cervical and Ovarian Cancers.
    Eur J Nucl Med Mol Imaging. 43(6):1047-1055, 2016.
  13. Thompson HM, Minamimoto R, Jamali M, Barkhodari A, von Eyben R, Iagaru A.
    A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners.
    Clin Nucl Med. 41(7):e323-326, 2016.
  14. Minamimoto R, Hancock S, Schneider B, Chin F, Jamali M, Loening AM, Vasanawala S, Gambhir SS, Iagaru A.
    Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA PET in Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 57(4):557-562, 2016.
  15. Tomomichi Iizuka, Masashi Kameyama .
    Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies.
    Ann Nucl Med. 2016.
  16. Tomomichi Iizuka , Masashi Kameyama.
    Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease Geriatrics and Gerontology International. 2016.
  17. Masashi Kameyama, Koji Murakami, Masahiro Jinzaki.
    Optimal HMPAO α value for Lassen's correction algorithm obscured by statistical noise.
    Ann Nucl Med 2016.
  18. Kenichiro Sato, Ayumi Hida, Masashi Kameyama, Miyako Morooka, Sousuke Takeuchi.
    Reduced 123I Ioflupane Binding in Bilateral Diabetic Chorea Findings With 18F FDG PET, 99mTc ECD SPECT, and 123I MIBG Scintigraphy.
    Clin Nucl Med. 41(6):481-482, 2016.

 

総説ー欧文

  1. Kameyama M, Murakami K, Jinzaki M. Comparison of [15O] H2O Positron Emission Tomography and Functional Magnetic Resonance Imaging in Activation Studies World J Nucl Med 15(1): 3-6. 2016.2.        
  2. Mansi R, Minamimoto R, Mäcke H, Iagaru AH. Bombesin-Targeted PET of Prostate Cancer. J Nucl Med. 57(Suppl 3):67S-72S, Oct, 2016.

総説ー和文

  1. 南本 亮吾,窪田 和雄. 新前立腺癌学 最新の基礎研究と診断・治療. Ⅷ. 前立腺癌の検査・診断, 5.画像診断(4), 新しい骨転移の画像診断. 日本臨牀, 日本臨牀社, 大阪, 74(3), p330-334, 2016.

 

単行本ー和文

  1. 南本亮吾, 窪田和雄. 肺癌 - ガイドラインに基づいた治療戦略と実地診療への活用: FDG PET/CTの上手な利用法. Medical Practice 33(2), 文光堂, 東京, p205-207, 2016.
  2. 南本亮吾、窪田和雄. 新前立腺癌学 最新の基礎研究と診断・治療. VIII.  前立腺癌の検査・診断,  5.画像診断(4), 新しい骨転移の画像診断. 日本臨牀, 日本臨牀社, 大阪, 74 (3),  p330-334,  2016.

 

雑誌ー和文

  1. 南本亮吾. 海外留学・研究報告 スタンフォード大学留学記. 臨床核医学11,p91-92,2016.

 

 

口頭・ポスター発表-国際学会・研究会

  1. Minamimoto R, Hotta M, Toyohara J, Okasaki M, Morooka M, Miyata Y, Kameyama M, Nakajima K, Miwa A, Kubota K.  Prospective Comparison of 11C-4DST, 18F-FDG PET/CT and Whole-body MRI in the Patients with Multiple Myeloma.  SNMMI annual meeting San Diego, 2016.
  2. Hotta M, Minamimoto R Toyohara J, Morooka M, Nakajima K , Kubota K.Pilot Comparison of 4DST and FDG PET/CT for Early Therapy Monitoring of Advanced Non Small Cell Lung Cancer.  RSNA 2016. Chicago, USA.
  3. Iagaru A, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanawala S. Biochemically recurrent prostate cancer: 68Ga-RM2 (formerly known as 68Ga-Bombesin or BAY86-7548) PET/MRI is superior to conventional imaging. SNMMI annual meeting San Diego, 2016.
  4. Sonni I, Minamimoto R, Jamali, M, Hatami N, Berndt M, Koglin N, Stephens A, Iagaru A, Chin F, Gambhir S, Mittra E. Imaging of tumor-associated system xC- activity with 18F-fluoropropylglutamate (18F-FSPG) PET/CT for intracranial malignancies. SNMMI annual meeting San Diego, 2016.
  5. Wu F, Baratto L, Minamimoto R, Advani R, Sabile J, Mittra E. Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT. SNMMI annual meeting San Diego, 2016.
  6. Sonni I, Minamimoto R, Loening A, Taviani V, Jamali M, Hatami N, Baratto L, Wu F, Gambhir S, Vasanawala S, Iagaru A. Imaging Patients with Breast and Prostate Cancers Using Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI. SNMMI annual meeting San Diego, 2016.
  7. Baratto L, Wu F, Minamimoto R, Sabile J, Advani R, Mittra E. Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients. SNMMI annual meeting San Diego, 2016.
  8. Baratto L, Wu F, Minamimoto R, Sabile J, Advani R, Mittra E. The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis. SNMMI annual meeting San Diego, 2016.
  9. Iagaru A, Sonni I, Minamimoto R, Loening A, Vasanawala S. Ga68 RM2 PET/MRI Evaluation of Gastrin-Releasing Peptide Receptor Status in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. EANM 2016.
  10. Sonni I, Minamimoto R, Tavian V, Loening A, Gambhir, S. Vasanawala S, Iagaru A. Imaging patients with breast and prostate cancers using combined 18F-NaF/18F-FDG and TOF simultaneous PET/MRI EANM 2016.
  11.  Sonni I, Minamimoto R, Jamali M, Mittra E Imaging of tumor-associated system xc- activity with 18Ffluoropropylglutamate (FSPG) PET/CT for intracranial malignancies. EANM, 2016.
  12. Hotta M, Minamimoto R, Toyohara J, Okazaki M, Morooka M, Kameyama M, Miwa A, Kubota K. Prospective comparison of 11C-4DST, 18-FDG PET/CT and whole-body MRI in the patients with multiple myeloma. SNMMI 2016 The Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, USA, June, 2016.
  13. Hotta M, Morooka M, Ishii K, Ito K, Sakata M, Kameyama M, Minamimoto R, Kubota K. Fingerprints of mild HIV-associated neurocognitive disorders (HAND): FDG and VBM study. SNMMI 2016 The Society of Nuclear Medicine and Molecular Imaging, San Diego, CA, USA, June, 2016.
  14. Hotta M, Yamada T, Shimizu T, Watanabe T, Harada A, Sato H, Yamashita A, Yokote H, Tsukuda S, Ohgi K. CT imaging features of congenital heart disease in children: What every radiologist should know. ARRS 2016 American Roentgen Ray Society Annual Meeting, Los Angeles, CA, USA, April, 2016.

 

 

口頭・ポスター発表-国内学会・研究会

  1. 窪田 和雄.
    神経内分泌腫瘍の核医学.
    長崎核医学研究会. 長崎, 2月, 2016.
  2. 南本 亮吾.
    68Ge/68Ga ジェネレータの臨床利用について.
    PETサマーセミナー. 熊本, 8月, 2016.
  3. 南本 亮吾.
    68Ge/68Ga ジェネレータの米国での臨床経験.
    PETサマーセミナー. 熊本, 8月, 2016.
  4. 水沼 文孝.
    オクトレオスキャンの使用経験.
    第898回放射線診療研究会. 東京, 9月, 2016.
  5. 南本 亮吾.
    English Presentation Boot Camp.
    日本放射線技術学会関東支部. 東京, 9月, 2016.
  6. 南本 亮吾.
    臨床におけるメチオニンPETの有用性.
    第56回日本核医学会学術総会. 愛知, 11月, 2016.
  7. 堀田 昌利,南本亮吾,諸岡都,亀山征史,中島和彦,砂岡史生,児玉清幸,梶原宏則,窪田和雄.
    ソマトスタチン受容体シンチグラフィ(111In-ペントテレオクチド)の生理的集積に関する検討.
    第56回日本核医学会学術総会. 愛知, 11月, 2016.
  8. 堀田 昌利,南本亮吾, 豊原潤, 諸岡都, 亀山征史, 中島和彦, 野原京子, 山田和彦, 窪田和雄.
    11C-4DSTと18F-FDGにおける食道癌お抽出能に関する比較検討.
    第56回日本核医学会学術総会. 愛知, 11月, 2016.

著書・総説

総説-英文

  1. Kameyama M, Murakami K, Jinzaki M.
    Comparison of [15O] H2O Positron Emission Tomography and Functional Magnetic Resonance Imaging in Activation Studies.
    World J Nucl Med 15(1): 3-6. 2016.

単行本-和文

  1. 南本 亮吾, 窪田 和雄.
    肺癌 - ガイドラインに基づいた治療戦略と実地診療への活用: FDG PET/CTの上手な利用法.
    Medical Practice. 33(2), 文光堂, 東京, p205-207, 2016.
  2. 南本 亮吾,窪田 和雄.
    新前立腺癌学 最新の基礎研究と診断・治療. Ⅷ.
    前立腺癌の検査・診断, 5.画像診断(4), 新しい骨転移の画像診断. 日本臨牀, 日本臨牀社, 大阪, 74(3), p330-334, 2016.

雑誌-和文

  1. 南本 亮吾.
    海外留学・研究報告 スタンフォード大学留学記.
    臨床核医学11月号.

その他

講演

  1. 南本 亮吾.
    English Presentation Boot Camp.
    第72回日本放射線技術学会総会学術大会. 横浜,4月, 2016.
  2. 南本 亮吾.
    English Presentation Boot Camp.
    第72回日本放射線技術学会総会学術大会. 横浜,4月, 2016.
  3. Ryogo Minamimoto.
    PET/MRI and Molecular Imaging.
    第11回日本分子イメージング学会総会・学術集会. 神戸, 5月28日, 2016.
  4. 南本 亮吾.
    PET/MRI時代を迎えて:日本のadvantageを考える.
    第11回日本分子イメージング学会総会・学術集会. 神戸, 5月29日, 2016.
  5. 南本 亮吾.
    SIGNA PET/MRの使用経験に基づくSiPM(silicon photomultiplier)の展望.
    PETサマーセミナー. 熊本, 8月, 2016.
  6. 南本 亮吾. MIM がもたらす核医学データ解析の新次元第56回日本核医学会学術総会. 愛知, 11月, 2016.
  7. 堀田昌利.PET検査の現状.京都医療科学大学 第61回関東支部総会,横浜,11月, 2016.